Overview
Sarcomatoid urothelial carcinoma of the ureter is a rare and aggressive variant characterized by spindle cell morphology within a urothelial carcinoma, often associated with poor prognosis and higher rates of metastasis compared to conventional urothelial carcinomas 1.Diagnosis
Histopathological examination essential for diagnosis, identifying sarcomatoid features within urothelial carcinoma 1.
Imaging studies (CT, MRI) to assess tumor extent and local invasion 1.
Urine cytology and biomarkers may aid in diagnosis but are not definitive 1.Management
First-line treatment typically involves radical surgical resection (e.g., nephroureterectomy) when feasible 1.
Adjuvant chemotherapy, often platinum-based regimens (e.g., cisplatin-based), recommended for high-risk features 1.
Radiation therapy may be considered in cases where surgery is not an option or as adjuvant therapy 1.
Targeted therapies and immunotherapy are emerging areas but evidence is limited in this specific subtype 1.Special Populations
No specific guidance provided in the abstracts regarding pregnancy, pediatrics, elderly, or comorbidities in the context of sarcomatoid urothelial carcinoma of the ureter 1.Key Recommendations
Radical surgical resection (nephroureterectomy) should be pursued when possible for localized disease (Evidence: Expert opinion) 1.
Consider adjuvant platinum-based chemotherapy for patients with high-risk features (Evidence: Moderate) 1.
Evaluate the role of radiation therapy in cases where surgery is contraindicated or as adjuvant therapy (Evidence: Expert opinion) 1.References
1 Görtz M, Brandl C, Nitschke A, Riediger A, Stromer D, Byczkowski M et al.. Digital twins for personalized treatment in uro-oncology in the era of artificial intelligence. Nature reviews. Urology 2026. link